Xintela AB
Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company's stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indicati… Read more
Xintela AB (XINT) - Net Assets
Latest net assets as of September 2025: Skr-27.88 Million SEK
Based on the latest financial reports, Xintela AB (XINT) has net assets worth Skr-27.88 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr9.08 Million) and total liabilities (Skr36.95 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr-27.88 Million |
| % of Total Assets | -307.15% |
| Annual Growth Rate | N/A |
| 5-Year Change | -121.55% |
| 10-Year Change | -179.75% |
| Growth Volatility | 123.9 |
Xintela AB - Net Assets Trend (2013–2024)
This chart illustrates how Xintela AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Xintela AB (2013–2024)
The table below shows the annual net assets of Xintela AB from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr-5.95 Million | -235.84% |
| 2023-12-31 | Skr4.38 Million | -24.18% |
| 2022-12-31 | Skr5.78 Million | +46.36% |
| 2021-12-31 | Skr3.95 Million | -85.70% |
| 2020-12-31 | Skr27.61 Million | +196.09% |
| 2019-12-31 | Skr9.32 Million | -79.25% |
| 2018-12-31 | Skr44.95 Million | +144.07% |
| 2017-12-31 | Skr18.41 Million | -12.24% |
| 2016-12-31 | Skr20.98 Million | +181.24% |
| 2015-12-31 | Skr7.46 Million | -21.81% |
| 2014-12-31 | Skr9.54 Million | +87.77% |
| 2013-12-31 | Skr5.08 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xintela AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40027730100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr19.97 Million | % |
| Other Comprehensive Income | Skr555.00K | % |
| Other Components | Skr376.56 Million | % |
| Total Equity | Skr-5.95 Million | 100.00% |
Xintela AB Competitors by Market Cap
The table below lists competitors of Xintela AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ornsirin Holding Public
BK:ORN
|
$7.16 Million |
|
NEXTCHIP Co. Ltd
KQ:092600
|
$7.16 Million |
|
Red Light Holland Corp
OTCQB:TRUFF
|
$7.16 Million |
|
Geohan Corporation Berhad
KLSE:5345
|
$7.16 Million |
|
Dogan Burda Dergi Yayincilik ve Pazarlama AS
IS:DOBUR
|
$7.15 Million |
|
Kantone Holdings Limited
PINK:KTHGF
|
$7.15 Million |
|
An Pha Petroleum Group JSC
VN:ASP
|
$7.15 Million |
|
Excel Force MSC Bhd
KLSE:0065
|
$7.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xintela AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,380,000 to -5,950,000, a change of -10,330,000 (-235.8%).
- Net loss of 39,190,000 reduced equity.
- Share repurchases of 29,594,000 reduced equity.
- New share issuances of 29,594,000 increased equity.
- Other comprehensive income decreased equity by 734,000.
- Other factors increased equity by 29,594,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-39.19 Million | -658.66% |
| Share Repurchases | Skr29.59 Million | -497.38% |
| Share Issuances | Skr29.59 Million | +497.38% |
| Other Comprehensive Income | Skr-734.00K | -12.34% |
| Other Changes | Skr29.59 Million | +497.38% |
| Total Change | Skr- | -235.84% |
Book Value vs Market Value Analysis
This analysis compares Xintela AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | Skr0.16 | Skr0.24 | x |
| 2014-12-31 | Skr0.29 | Skr0.24 | x |
| 2015-12-31 | Skr0.25 | Skr0.24 | x |
| 2016-12-31 | Skr0.50 | Skr0.24 | x |
| 2017-12-31 | Skr0.37 | Skr0.24 | x |
| 2018-12-31 | Skr0.78 | Skr0.24 | x |
| 2019-12-31 | Skr0.13 | Skr0.24 | x |
| 2020-12-31 | Skr0.34 | Skr0.24 | x |
| 2021-12-31 | Skr0.03 | Skr0.24 | x |
| 2022-12-31 | Skr0.03 | Skr0.24 | x |
| 2023-12-31 | Skr0.01 | Skr0.24 | x |
| 2024-12-31 | Skr-0.01 | Skr0.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xintela AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -929.77%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-418.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -44.84% | 0.00% | 0.00x | 1.39x | Skr-2.79 Million |
| 2014 | -31.52% | -29992.53% | 0.00x | 1.10x | Skr-3.96 Million |
| 2015 | -154.93% | -1526.95% | 0.07x | 1.42x | Skr-12.31 Million |
| 2016 | -86.07% | -602000.00% | 0.00x | 1.14x | Skr-20.16 Million |
| 2017 | -119.17% | -1097250.00% | 0.00x | 1.55x | Skr-23.79 Million |
| 2018 | -58.46% | -1613.88% | 0.03x | 1.11x | Skr-30.77 Million |
| 2019 | -467.05% | -114600.00% | 0.00x | 1.83x | Skr-44.48 Million |
| 2020 | -191.71% | 0.00% | 0.00x | 1.76x | Skr-55.68 Million |
| 2021 | -1493.08% | 0.00% | 0.00x | 6.27x | Skr-59.33 Million |
| 2022 | -1146.22% | 0.00% | 0.00x | 4.24x | Skr-66.79 Million |
| 2023 | -1234.77% | -69337.18% | 0.00x | 4.20x | Skr-54.52 Million |
| 2024 | 0.00% | -929.77% | 0.17x | 0.00x | Skr-38.59 Million |
Industry Comparison
This section compares Xintela AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xintela AB (XINT) | Skr-27.88 Million | -44.84% | N/A | $7.16 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |